All the Active Ingredient Drugs
Monoclonal Antibody. Mepolizumab 100 mg. VIAL: 1 or 3 X 100 mg Pre-filled pen: 1 or 3 X 1ml
100 mg SC once every 4 weeks.
Limitations for COPD: may be used in pts with an eosinophil level above 150 cells/μL.
Sev. eosinophilic asthma :as add-on for sev. refract. eosinophilic asthma in adlts. Chron. rhinosinusitis with nasal polyps (CRSwNP):as add-on with intranasal corticost. for adlts with sev. CRSwNP for whom ther. with corticost. and surgery in the last 10 years do not provide adeq. dis. ctrol. Eosinophilic Granulomatosis with Polyangiitis (EGPA): for adlts with eosinophilic granulomatosis with polyangiitis (EGPA). Hypereosinophilic syndrome (HES) :as add-on for adlts with inadeq. ctrolled hypereosinophilic syndr. w/o an identifiable non-haematologic second. Cause
Pre-filled pen- Chron. obstructive pulm. disease (COPD): as add-on maint. tmt of adlts with inadeq. ctrolled chron. obstructive pulm. dis. with an eosinophilic phenotype.
C/I: Hypersens.
